qn-030a
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 28, 2022 (NCT05601830)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05665114 | Phase 1 | Dec 15, 2022 | Hangzhou Qihan Biotech Co.,Ltd., Zhejiang University |
| NCT05601830 | Phase 1 | Oct 28, 2022 | Chinese Academy of Medical Sciences |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Hangzhou Qihan Biotech Co.,Ltd. | For profit | 1 | 0 | 1 | 2022 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1